Medtronic Guides FY26 Adj. EPS Below View; Intends To Separate Diabetes Business

Medtronic (MDT) projects FY26 adjusted EPS of $5.50-$5.60 and revenue growth of 4.8-5.1% (organic growth of ~5.0%), below the $5.83 analyst consensus. The guidance considers potential impacts from US/China tariffs, with the lower end assuming higher rates resume. Medtronic also announced a dividend increase to $0.71 per share and plans to spin off its Diabetes business into a new public company within 18 months, favoring an IPO and subsequent split-off.

Analysis

Medtronic plc has issued its fiscal year 2026 guidance, projecting adjusted earnings per share between $5.50 and $5.60, a range notably below the $5.83 analyst consensus. This earnings outlook contrasts with an anticipated revenue growth of 4.8% to 5.1%, translating to organic revenue growth of approximately 5.0%, which aligns with or slightly exceeds the consensus estimate of 4.5% revenue growth. The company explicitly states that the earnings guidance range reflects uncertainty surrounding U.S./China tariffs: the lower bound assumes higher tariffs resume following the current 90-day pause, while the upper bound anticipates current paused rates continue through fiscal year 2026. Alongside this financial outlook, Medtronic announced a positive development for income investors with an increased quarterly cash dividend to $0.71 per share, payable on July 11, 2025. In a significant strategic move, Medtronic also declared its intention to separate its Diabetes business into a new standalone public company within the next 18 months, with an initial public offering and subsequent split-off being the preferred pathway, as part of its ongoing portfolio management strategy aimed at optimizing value.

Key Decisions for Investors

• Investors should closely monitor developments regarding U.S./China tariffs, as their resolution will be a key determinant for Medtronic's profitability and its ability to achieve the higher end of its FY26 EPS guidance.
• The planned spin-off of the Diabetes business presents a potential long-term value creation opportunity through focused operations, though investors should assess the execution timeline and the distinct market profiles of the two resulting entities.
• Despite the FY26 EPS guidance falling short of consensus, the robust organic revenue growth forecast and the increased dividend may offer a degree of support, warranting a careful evaluation of the risk/reward profile in light of the tariff uncertainties and strategic restructuring.